Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Selenium-binding protein 1 transcriptionally activates p21 expression via p53-independent mechanism and its frequent reduction associates with poor prognosis in bladder cancer

Fig. 1

SELENBP1 is frequently down-regulated in human bladder cancer, and low expression of SELENBP1 predicts poor clinical prognosis. a Twelve pairs of bladder cancers (T) and adjacent matched normal tissues (N) were extracted and subjected to immunoblotting assay for determining the levels of SELENBP1 protein expression. GAPDH was used as a loading control. b Relative intensity of SELENBP1 in a was determined using Quantity One software, and normalized to GAPDH. The relative intensity of SELENBP1 in normal tissues was set to 1.0. Paired t test was performed and p value was indicated in top panel. cSELENBP1 mRNA levels were extracted from TCGA bladder cancer (TCGA-BLCA) cohort, including 19 of normal bladder tissues and 406 of bladder cancer tissues. Non-paired t test was performed and p value was indicated in the panel. d Kaplan–Meier 10-year survival analysis among patients with high and low SELENBP1 expression in TCGA-BLCA cohort. The log-rank test was performed and p value was indicated in the panel. Hazard ration (HR) and 95% confidence interval (CI) were also calculated

Back to article page